Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
Sedentary obesity is associated with increased risk of many cardio-metabolic diseases, including type 2 diabetes. Weight loss is therefore a desirable goal for sedentary adults with obesity. Weight loss is also a well-documented side effect of sodium glucose co-transporter 2 (SGLT2) inhibition, a ph...
Main Authors: | Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/12/2/510 |
Similar Items
-
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
by: Dustin M. Lee, et al.
Published: (2018-04-01) -
Short Communication: Immunohistochemical study of sodium-dependent glucose co-transporters in ostriches kidneys
by: Piret Hussar, et al.
Published: (2020-12-01) -
Candida sepsis from local infection in a patient with a urostomy on SGLT2 inhibitor therapy
by: Ralph Wendt, et al.
Published: (2020-09-01) -
The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018-11-01) -
Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes
by: Bolge SC, et al.
Published: (2017-06-01)